Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lipitor Clear all

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 20
States / cities: Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more

Conditions: Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance
Interventions: atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, placebo/placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 85 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hearing Loss, Head and Neck Cancer
Interventions: Placebo, Atorvastatin; Other · Drug
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more

Conditions: HIV Dementia
Interventions: Atorvastatin (generic Lipitor), placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain
Interventions: Succinylcholine; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension, Dyslipidemia
Interventions: Caduet; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 34
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Garden Grove, California + 30 more

Conditions: Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hyperlipidemia, Insulin Resistance, Type 2 Diabetes
Interventions: Atorvastatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 20 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Hartford, Connecticut • Storrs, Connecticut • Amherst, Massachusetts

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, Ezetimibe, Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more

Conditions: HIV
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: San Diego, California • Bethesda, Maryland

Conditions: Healthy
Interventions: Sitagliptin, atorvastatin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cardiovascular Diseases
Interventions: AMR101, Placebo, Statin therapy; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 8,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 176
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more

Conditions: Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions: Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 70 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more

Conditions: Vascular Disease, Vascular Disease Risk
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV-1 Infection
Interventions: atorvastatin, placebo for atorvastin; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more

Conditions: Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 127
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 124 more

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more

Conditions: Alzheimer's Disease
Interventions: atorvastatin, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Sickle Cell Disease, Sickle Cell Nephropathy
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Scleroderma
Interventions: atorvastatin, Placebo; Drug
Lead sponsor: Robyn T. Domsic, MD, MPH; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Adults
Interventions: PF-06882961, Atorvastatin, Midazolam, Levonorgestrel & Ethinyl Estradiol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Systemic Lupus Erythematosus
Interventions: Atorvastatin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Metabolic Syndrome X, Hypercholesterolemia
Interventions: Atorvastatin, Pravastatin; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

ARREST PAD (Peripheral Arterial Disease)

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)

Effect of Succinylcholine on Patients Using Statins

Caduet in an Untreated Subject Population

Genetic Influence on Statin Pharmacodynamics

Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

The Effect of Statin Medications on Muscle Performance (The STOMP Study)

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy

The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

Effect of Atorvastatin (Lipitor) on Gene Expression in People With Vascular Disease

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

Cerebral and Peripheral Perfusion Pilot Study

Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease

Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

Lupus Atherosclerosis Prevention Study

Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells